Antibodies
22 August 2024
Monopar Receives Clearance to Proceed with Phase 1 Therapeutic Trial of Novel Radiopharmaceutical in Advanced Cancers21 August 2024
Kelun-Biotech’s TROP2-ADC SKB264 (sac-TMT) Second NDA Accepted by NPMA, locally advanced or metastatic EGFR-mutant NSCLC20 August 2024
Lift of Partial Clinical Hold for BNT326/YL20216 August 2024
BITT Announced CD40 Otsuka Research and Exclusivity Agreement and New NIH Funding for TNFR2 Clinical Trial16 August 2024
Imfinzi approved in the US for the treatment of resectable non-small cell lung cancer before and after surgery14 August 2024
Immutep Announces First Participant Dosed in Phase I Study of IMP761, a First in Class Agonist LAG-3 Antibody13 August 2024
Galderma Receives U.S. FDA Approval for Nemluvio® (nemolizumab) for Adult Patients Living With Prurigo Nodularis12 August 2024
Sandoz receives FDA approval for Enzeevu™ (aflibercept-abzv), further strengthening US biosimilar position9 August 2024
Merck to Acquire Investigational B-Cell Depletion Therapy, CN201, from Curon Biopharmaceutical9 August 2024
Abzena Supplies Clinical Trial Material for Angiex’s Phase I Study of AGX101, a First-in-Class TM4SF1-directed ADCNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports